China NMPA Guidance on the Management of Clinical Trials of Medical Products During COVID-19 Pandemic

On 14 July 2020 the Chine NMPA issued the draft guidance in Chinese for sponsors and investigators.

In order to standardize the clinical trials of drugs during COVID-19 pandemic in China and provide effective safety management measures, under the deployment and approval of the National Medical Products Administration (NMPA), the NMPA Drug Review Center has issued the draft guidance, which is in effect on the date of release.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /